Latest on Pharmaceutical Industry


U.S. FDA panel backs Puma Biotech's breast cancer drug

Puma Biotechnology Inc's experimental breast cancer drug reduces the risk of disease recurrence and should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Wednesday. The pa..Read More...

J&J settles drug manufacturing probe by U.S. states for $33 million

Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind several over-the-counter drugs that were eventually recalled. The settle..Read More...



International Conference and Exhibition on Nanomedicine and Drug Delivery 2017

Hyatt Regency Osaka,
Japan ,
Conferenceseries Ltd


Market Access for Precision Medicine

Hilton Crystal City,
Hanson Wade

Press Releases

Recro Gainesville Expands Manufacturing Capabilities with New Tableting Equipment and Growing Development Team

Recro Gainesville LLC a whollyowned subsidiary of Recro Pharma Inc has expanded its capabilities by adding a new tablet manufacturing suite and growing its development team An FDA and DEAapproved leading provider of soli.. Read More...

OrphoMed Secures $39 Million Series A Financing Round

OrphoMed Inc a clinical stage biopharmaceutical company developing firstinclass dimer therapies today announced the completion of a 39 million Series A financing The round was led by New Enterprise Associates NEA and col.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics